← Human Trials & Peer-Reviewed Studies
CGRP plasma level changes in patients with temporomandibular disorders treated with occlusal splints - a randomised clinical trial
Plain-language guide to PMID 24971923 (2014): randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide) in 35 subjects.
Key Facts
- PMID
- 24971923
- Journal
- Endokrynologia Polska
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Nitecka-Buchta A et al. (3 authors)
- DOI
- 10.5603/EP.2014.0030
What This Study Did, in Plain Language
What Was Tested
Researchers studied CGRP (Calcitonin Gene-Related Peptide) in this randomized controlled trial publication.
The aim of this study was to evaluate the plasma level of CGRP in patients with myofascial pain (RDC/TMD Ia) and myofascial pain with limited opening (RDC/TMD Ib) before and after muscle stretching with occlusal splint therapy.
Why It Was Studied
Occlusal splint therapy is a well-known method for the treatment of TMD.
Muscle stretching and pain relief are effects of occlusal appliance.
Who Took Part
The abstract describes 35 subjects taking part.
The age groups tagged for this paper are adults, middle-aged adults and older adults, women only.
A randomised trial was performed including 35 subjects (males = 10, females = 25) in the experimental group and 30 subjects (males = 9, females = 21) in the control group.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.
A time span of 30 days appears in the methods.
Blood samples were taken from the external jugular vein before and after 30 days of occlusal splint therapy.
What Was Measured
PubMed files the paper under topics including Calcitonin Gene-Related Peptide, Facial Pain, Occlusal Splints and Temporomandibular Joint Dysfunction Syndrome.
What This Means in Plain Language
The paper is a randomized study of CGRP (Calcitonin Gene-Related Peptide) in 35 subjects over 30 days.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2014 (Endokrynologia Polska), a journal based in Poland.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.